Coordination of iron homeostasis by bone morphogenetic proteins: Current understanding and unanswered questions
- PMID: 33993583
- PMCID: PMC8594283
- DOI: 10.1002/dvdy.372
Coordination of iron homeostasis by bone morphogenetic proteins: Current understanding and unanswered questions
Abstract
Iron homeostasis is tightly regulated to balance the iron requirement for erythropoiesis and other vital cellular functions, while preventing cellular injury from iron excess. The liver hormone hepcidin is the master regulator of systemic iron balance by controlling the degradation and function of the sole known mammalian iron exporter ferroportin. Liver hepcidin expression is coordinately regulated by several signals that indicate the need for more or less iron, including plasma and tissue iron levels, inflammation, and erythropoietic drive. Most of these signals regulate hepcidin expression by modulating the activity of the bone morphogenetic protein (BMP)-SMAD pathway, which controls hepcidin transcription. Genetic disorders of iron overload and iron deficiency have identified several hepatocyte membrane proteins that play a critical role in mediating the BMP-SMAD and hepcidin regulatory response to iron. However, the precise molecular mechanisms by which serum and tissue iron levels are sensed to regulate BMP ligand production and promote the physical and/or functional interaction of these proteins to modulate SMAD signaling and hepcidin expression remain uncertain. This critical commentary will focus on the current understanding and key unanswered questions regarding how the liver senses iron levels to regulate BMP-SMAD signaling and thereby hepcidin expression to control systemic iron homeostasis.
Keywords: BMP; anemia; hemochromatosis; hepcidin; iron sensing; liver.
© 2021 American Association for Anatomy.
Conflict of interest statement
Conflict of interest disclosures
JLB has been a consultant for Disc Medicine, Incyte Corporation, and Alnylam Pharmaceuticals, and owns equity in Ferrumax Pharmaceuticals, a company focused on targeting RGM proteins (including hemojuvelin) and bone morphogenetic protein (BMP/TGF-beta) superfamily signaling as hepcidin modulating agents for the treatment of anemia and other iron disorders. Dr. Babitt’s interests were reviewed and are managed by Massachusetts General Hospital and Mass General Brigham in accordance with their conflict-of-interest policies. ALF declares no conflict of interest.
Figures


Similar articles
-
Bone morphogenic proteins in iron homeostasis.Bone. 2020 Sep;138:115495. doi: 10.1016/j.bone.2020.115495. Epub 2020 Jun 23. Bone. 2020. PMID: 32585319 Free PMC article. Review.
-
Bone morphogenetic protein 2 controls iron homeostasis in mice independent of Bmp6.Am J Hematol. 2017 Nov;92(11):1204-1213. doi: 10.1002/ajh.24888. Epub 2017 Sep 25. Am J Hematol. 2017. PMID: 28815688 Free PMC article.
-
Hepcidin-mediated hypoferremic response to acute inflammation requires a threshold of Bmp6/Hjv/Smad signaling.Blood. 2018 Oct 25;132(17):1829-1841. doi: 10.1182/blood-2018-03-841197. Epub 2018 Sep 13. Blood. 2018. PMID: 30213871
-
The hepcidin-ferroportin axis modulates liver endothelial cell BMP expression to influence iron homeostasis in mice.Blood. 2025 Feb 6;145(6):625-634. doi: 10.1182/blood.2024024795. Blood. 2025. PMID: 39437541
-
Hepcidin and the BMP-SMAD pathway: An unexpected liaison.Vitam Horm. 2019;110:71-99. doi: 10.1016/bs.vh.2019.01.004. Epub 2019 Feb 10. Vitam Horm. 2019. PMID: 30798817 Review.
Cited by
-
Transgenic augmentation of erythroferrone in mice ameliorates anemia in adenine-induced chronic kidney disease.bioRxiv [Preprint]. 2024 Dec 10:2024.12.06.627111. doi: 10.1101/2024.12.06.627111. bioRxiv. 2024. Update in: JCI Insight. 2025 Aug 7:e190018. doi: 10.1172/jci.insight.190018. PMID: 39713359 Free PMC article. Updated. Preprint.
-
Cytochrome P450 1B1: A Key Regulator of Ocular Iron Homeostasis and Oxidative Stress.Cells. 2022 Sep 20;11(19):2930. doi: 10.3390/cells11192930. Cells. 2022. PMID: 36230892 Free PMC article. Review.
-
Live-Cell Invasive Phenotyping Uncovers ALK2 as a Therapeutic Target in LKB1-Mutant Lung Cancer.Cancer Res. 2024 Nov 15;84(22):3761-3771. doi: 10.1158/0008-5472.CAN-23-2631. Cancer Res. 2024. PMID: 39207369 Free PMC article.
-
HFE-Related Hemochromatosis May Be a Primary Kupffer Cell Disease.Biomedicines. 2025 Mar 10;13(3):683. doi: 10.3390/biomedicines13030683. Biomedicines. 2025. PMID: 40149659 Free PMC article. Review.
-
Iron Deficiency Anemia.Adv Exp Med Biol. 2025;1480:163-178. doi: 10.1007/978-3-031-92033-2_12. Adv Exp Med Biol. 2025. PMID: 40603791 Review.
References
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources